Oncologists and research labs are struggling to keep up with demand for chimeric antigen receptor T-cell therapy as more clinical trials get underway and desperately ill patients seek access to the promising therapy. The investigational approach, which involves the time-consuming and expensive process of genetically engineering autologous immune cells, is risky but has shown strong results, especially in patients with lymphoma.
Scientists struggle to keep up with demand for CAR T therapy
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.